Indian Indapamide Market Trends, Research Report, Growth, Opportunities, Forecast 2022-2028

 

Indian indapamide market is estimated to grow at a CAGR of around 4.0% during the forecast period owing to the significant prevalence of chronic diseases in the region. According to the Cardiological Society of India, the Trivandrum heart failure registry had registered 1,205 admissions due to heart failure in 2018, of which 834 in men, indicating around 69% of total heart failures in Trivandrum. In addition, the most common cause of heart failure includes ischemic heart disease, which is accounted for 72% of heart failures in India in 2018. Heart failure with preserved ejection fraction (HFpEF) accounted for 26%. This, in turn, is expected to drive the demand for indapamide tablets that enable to treat fluid retention (edema) in patients suffering from congestive heart failure.

To learn more about this report request a sample copy @ https://www.omrglobal.com/industry-reports/indian-indapamide-market

Indian indapamide market is segmented on the basis of product and application. Based on the product, the market is bifurcated into 1.25 mg indapamide and 2.5 mg indapamide. Among these, the market for 1.25 mg indapamide held a significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have a significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.

The companies which are contributing to the growth of the Indian indapamide market include Glenmark Pharmaceuticals Ltd, Shandong Yinfeida Pharmaceutical Co., Ltd., Suzhou Lixin Pharmaceutical Co., Ltd., Merck KGaA, Sanofi S.A.,  and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations to stay competitive in the market.

Indian Indapamide Market- Segmentation

By Product

·         1.25 MG

·         2.5 MG

By Application

·         High Blood Pressure

·         Heart Failure

·         Others

A full report of Indian Indapamide Market is available at: https://www.omrglobal.com/industry-reports/indian-indapamide-market

Company Profiles

·         ANI Pharmaceuticals, Inc.

·         Glenmark Pharmaceuticals Ltd.

·         Merck KGaA

·         Sandoz International GmbH

·         Sanofi S.A.

·         Shandong Yinfeida Pharmaceutical Co., Ltd.

·         Supra Chemicals

·         Suzhou Lixin Pharmaceutical Co., Ltd.

·         Taj Pharmaceuticals Ltd.

·         Torrent Pharmaceuticals Ltd.

Reasons to Buying From us –

1.       We cover more than 15 major industries, further segmented into more than 90 sectors.

2.       More than 120 countries are for analysis.

3.       Over 100+ paid data sources mined for investigation.

4.       Our expert research analysts answer all your questions before and after purchasing your report.

 

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

 

Media Contact:

Contact Person: Mr. Anurag Tiwari

Email: anurag@omrglobal.com

Contact no: +91 780-304-0404

Company Name: Orion Market Research